Abstract
Male breast cancer is rare, accounting for 1% of all breast cancer diagnoses in the USA. Because of its rarity, most major breast cancer trials have included only female patients. This has resulted in limited prospective data to guide the clinical management of men with breast cancer. As a result, treatment decisions are typically extrapolated from data generated in female patients. This approach may be suboptimal, particularly considering the differing hormonal milieus between men and women with respect to both breast cancer development and treatment. Herein, we summarize current knowledge of the biology and clinicopathology of male breast cancer and review current approaches to locoregional and systemic management of this rare disease.
Original language | English (US) |
---|---|
Pages (from-to) | 599-614 |
Number of pages | 16 |
Journal | Cancer and Metastasis Reviews |
Volume | 37 |
Issue number | 4 |
DOIs | |
State | Published - Dec 15 2018 |
Keywords
- BRCA
- Chemotherapy
- Endocrine therapy
- Epidemiology
- Male breast cancer
- Radiation therapy
- Surgery
ASJC Scopus subject areas
- Oncology
- Cancer Research